Business Description
Neovacs SA
NAICS : 325412
SIC : 2834
ISIN : FR001400TG47
Compare
Compare
Traded in other countries / regions
ALNEV.France0LW.Germany0W8U.UK IPO Date
2011-05-24Description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.48 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -3.08 | |||||
| Beneish M-Score | -2469.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 96.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.77 | |||||
| 9-Day RSI | 33.37 | |||||
| 14-Day RSI | 36.69 | |||||
| 6-1 Month Momentum % | -98.9 | |||||
| 12-1 Month Momentum % | -99.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.66 | |||||
| Quick Ratio | 0.66 | |||||
| Cash Ratio | 0.05 | |||||
| Days Sales Outstanding | 156.22 | |||||
| Days Payable | 2259.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1194.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.22 | |||||
| Operating Margin % | -1533.16 | |||||
| Net Margin % | -4683.09 | |||||
| FCF Margin % | -222.46 | |||||
| ROE % | -91.1 | |||||
| ROA % | -69.3 | |||||
| ROIC % | -24.26 | |||||
| ROC (Joel Greenblatt) % | -7364.33 | |||||
| ROCE % | -77.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.01 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-Revenue | 0.47 | |||||
| EV-to-FCF | -0.22 | |||||
| Earnings Yield (Greenblatt) % | -10224.72 | |||||
| FCF Yield % | -1573.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neovacs SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.757 | ||
| EPS (TTM) (€) | -160656.5 | ||
| Beta | 0 | ||
| Volatility % | 100.04 | ||
| 14-Day RSI | 36.69 | ||
| 14-Day ATR (€) | 0.580643 | ||
| 20-Day SMA (€) | 1.85913 | ||
| 12-1 Month Momentum % | -99.99 | ||
| 52-Week Range (€) | 1 - 32000 | ||
| Shares Outstanding (Mil) | 0.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neovacs SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neovacs SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neovacs SA Frequently Asked Questions
What is Neovacs SA(XPAR:ALNEV)'s stock price today?
The current price of XPAR:ALNEV is €1.12. The 52 week high of XPAR:ALNEV is €32000.00 and 52 week low is €1.00.
When is next earnings date of Neovacs SA(XPAR:ALNEV)?
The next earnings date of Neovacs SA(XPAR:ALNEV) is .
Does Neovacs SA(XPAR:ALNEV) pay dividends? If so, how much?
Neovacs SA(XPAR:ALNEV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers